The promise of retatrutide is that a single molecule may coordinate several pathways at once
Shelf life: Under appropriate storage conditions, retatrutide maintains stability and potency for optimal research use
Achievement of normal liver fat content (less than 5%) occurred in 27% of participants receiving 1 mg, 52% receiving 4 mg, 79% receiving 8 mg, and 86% receiving 12 mg at 24 weeks, compared to 0% with placebo
It is a safety requirement
Overall, GLP-1 patches represent a significant advancement in the management of obesity and diabetes, offering a reliable and effective solution for those looking to improve their health.
Research has also explored how tri-agonist signaling may affect fat distribution and body composition parameters, including visceral adiposity and total fat mass